Gilead stock rated buy for thriving HIV biz, promising oncology pipeline, and long-term growth potential despite volatility.
Gilead said Tuesday that it will soon begin Phase 3 testing for a drug it believes could prevent HIV infection with just a single shot every year. Such a medicine, if proven effective, would be ...
A new drug is hugely effective at protecting people from HIV infection and needs to be injected only twice a year.
Irish Independent on MSN2d
Gilead gives its blessing to Poolbeg Pharma’s Hookpia merger dealUS biopharmaceuticals giant Gilead has thrown its weight behind a potential merger of Ireland’s Poolbeg Pharma and Austria ...
(Yicai) Jan. 3 -- US pharmaceutical company Gilead Sciences has been given the greenlight by Chinese regulators to sell its ...
Lenacapavir, approved by the US FDA, presents a groundbreaking advancement in the battle against HIV. Developed by Gilead ...
A Guideline Development Group (GDG) meeting at the end of the month aims to establish new guidelines for lenacapavir, a twice ...
The US drug administration has approved the use of the medication as an injection for use against the multidrug resistant ...
GS-2121 is under clinical development by Gilead Sciences and currently in Phase I for Solid Tumor. According to GlobalData, Phase I drugs for Solid Tumor have a 69% phase transition success rate (PTSR ...
Uganda is registering around 38,000 new infections despite the deployment of different interventions such as condoms and oral ...
CWA Asset Management Group LLC boosted its position in shares of Gilead Sciences, Inc. (NASDAQ:GILD – Free Report) by 1.5% in ...
Macroeconomic factors have weighed on US stocks in the final days of the year, with the broader market declining by over 1% ...
Results that may be inaccessible to you are currently showing.
Hide inaccessible results
Feedback